14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome
Copyright © 2014 Elsevier B.V. All rights reserved..
Pregnancy morbidity is one of the clinical manifestations used for classification criteria of antiphospholipid syndrome (APS). During the 14th International Congress on Antiphospholipid Antibodies (aPL), a Task Force with internationally-known experts was created to carry out a critical appraisal of the literature available regarding the association of aPL with obstetric manifestations present in actual classification criteria (recurrent early miscarriage, fetal death, preeclampsia and placental insufficiency) and the quality of the evidence that treatment(s) provide benefit in terms of avoiding recurrent adverse obstetric outcomes. The association of infertility with aPL and the effectiveness of the treatment of patients with infertility and positive aPL was also investigated. This report presents current knowledge and limitations of published studies regarding pregnancy morbidity, infertility and aPL, identifying areas that need better investigative efforts and proposing how critical flaws could be avoided in future studies, as suggested by participants of the Task Force. Except for fetal death, there are limitations in the quality of the data supporting the association of aPL with obstetric complications included in the current APS classification criteria. Recommended treatments for all pregnancy morbidity associated to APS also lack well-designed studies to confirm its efficacy. APL does not seem to be associated with infertility and treatment does not improve the outcomes in infertile patients with aPL. In another section of the Task Force, Dr. Jane Salmon reviewed complement-mediated inflammation in reproductive failure in APS, considering new therapeutic targets to obstetric APS (Ob APS).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 13(2014), 8 vom: 21. Aug., Seite 795-813 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Jesus, Guilherme R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Antiphospholipid |
|---|
| Anmerkungen: |
Date Completed 27.10.2014 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2014.02.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM236592742 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM236592742 | ||
| 003 | DE-627 | ||
| 005 | 20231224105905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2014.02.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0788.xml |
| 035 | |a (DE-627)NLM236592742 | ||
| 035 | |a (NLM)24650941 | ||
| 035 | |a (PII)S1568-9972(14)00092-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Jesus, Guilherme R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2014 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2014 Elsevier B.V. All rights reserved. | ||
| 520 | |a Pregnancy morbidity is one of the clinical manifestations used for classification criteria of antiphospholipid syndrome (APS). During the 14th International Congress on Antiphospholipid Antibodies (aPL), a Task Force with internationally-known experts was created to carry out a critical appraisal of the literature available regarding the association of aPL with obstetric manifestations present in actual classification criteria (recurrent early miscarriage, fetal death, preeclampsia and placental insufficiency) and the quality of the evidence that treatment(s) provide benefit in terms of avoiding recurrent adverse obstetric outcomes. The association of infertility with aPL and the effectiveness of the treatment of patients with infertility and positive aPL was also investigated. This report presents current knowledge and limitations of published studies regarding pregnancy morbidity, infertility and aPL, identifying areas that need better investigative efforts and proposing how critical flaws could be avoided in future studies, as suggested by participants of the Task Force. Except for fetal death, there are limitations in the quality of the data supporting the association of aPL with obstetric complications included in the current APS classification criteria. Recommended treatments for all pregnancy morbidity associated to APS also lack well-designed studies to confirm its efficacy. APL does not seem to be associated with infertility and treatment does not improve the outcomes in infertile patients with aPL. In another section of the Task Force, Dr. Jane Salmon reviewed complement-mediated inflammation in reproductive failure in APS, considering new therapeutic targets to obstetric APS (Ob APS) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antiphospholipid syndrome | |
| 650 | 4 | |a Complement | |
| 650 | 4 | |a Fetal death | |
| 650 | 4 | |a Infertility | |
| 650 | 4 | |a Preeclampsia | |
| 650 | 4 | |a Recurrent early miscarriage | |
| 650 | 7 | |a Antibodies, Antiphospholipid |2 NLM | |
| 700 | 1 | |a Agmon-Levin, Nancy |e verfasserin |4 aut | |
| 700 | 1 | |a Andrade, Carlos A |e verfasserin |4 aut | |
| 700 | 1 | |a Andreoli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Chighizola, Cecilia B |e verfasserin |4 aut | |
| 700 | 1 | |a Porter, T Flint |e verfasserin |4 aut | |
| 700 | 1 | |a Salmon, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Silver, Robert M |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Branch, D Ware |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 13(2014), 8 vom: 21. Aug., Seite 795-813 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2014 |g number:8 |g day:21 |g month:08 |g pages:795-813 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2014.02.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2014 |e 8 |b 21 |c 08 |h 795-813 | ||